Investigational Drug Information for Fasinumab
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Fasinumab?
Fasinumab is an investigational drug.
There have been 10 clinical trials for Fasinumab.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 30th 2017.
The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Hip, and Osteoarthritis, Knee. The leading clinical trial sponsors are Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Mitsubishi Tanabe Pharma Corporation.
There are two US patents protecting this investigational drug.
Summary for Fasinumab
| US Patents | 2 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2017-10-30) |
| Vendors | 0 |
Recent Clinical Trials for Fasinumab
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Teva Pharmaceutical Industries, Ltd. | Phase 2 |
| Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Regeneron Pharmaceuticals | Phase 2 |
| To Assess the Patients' Ability to Self-Administer Fasinumab | Teva Pharmaceutical Industries, Ltd. | Phase 1 |
Clinical Trial Summary for Fasinumab
Top disease conditions for Fasinumab
Top clinical trial sponsors for Fasinumab
US Patents for Fasinumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fasinumab | See Plans and Pricing | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| Fasinumab | See Plans and Pricing | Cell culture medium | LA JOLLA BIOLOGICS, INC. (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
